Showing results (51-60 of 180) with videos related to

Sort By:
Pageof 18
British Journal of Haematology|June 12, 2020
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myelomaCeri Bygrave, Charlotte Pawlyn, Faith Davies, et al.
Blood Cancer Journal|April 2, 2022
Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial resultsHolger W Auner, Sarah R Brown, Katrina Walker, et al.
British Journal of Haematology|September 2, 2011
Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantationDavid I Marks, Antonio Pagliuca, Christopher C Kibbler, et al.
Journal of Clinical Microbiology|July 3, 2009
Utility of a commercially available multiplex real-time PCR assay to detect bacterial and fungal pathogens in febrile neutropeniaMarie von Lilienfeld-Toal, Lutz E Lehmann, Ansgar D Raadts, et al.
Haematologica|January 29, 2026
Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based studyEve Roman, Timothy Bagguley, Simon Crouch, et al.
BMC Cancer|August 8, 2025
Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial dataMartin Kortüm, Sebastian Theurich, James Farrell, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 1, 2021
Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI TrialSarah Bird, David Cairns, Tom Menzies, et al.
British Journal of Haematology|April 27, 2012
Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009John A Snowden, Rachel M Pearce, Julia Lee, et al.
Pharmacoeconomics|October 29, 2025
A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry DataAdam Irving, Dennis Petrie, Anthony Harris, et al.
British Journal of Haematology|June 16, 2026
Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trialAndrew Hall, James Croft, Katrina Walker, et al.
Pageof 18